By Justin Petrone

Still not interested in getting into the next-generation sequencing market, Affymetrix will instead continue to focus on making more flexible genotyping and gene-expression array formats and on new Panomics kits, according to the firm's CEO.

Kevin King said that while Affy may revisit the idea of becoming a player in the next-gen sequencing market "perhaps in the future," its current focus is on "leading in exploration and growing our business in validation and routine testing."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Changing the fat and fiber content of people's diets affects their gut microbiome, metabolome, and colon cancer risk, researchers say.

Broken links are found throughout academic publications, and some services are trying to combat such link decay.

Nick Stockton at Wired says that a pause in studying genome-editing tools should be used to find a path forward.

In PNAS this week: genomic study of group B Streptococcus evolution, selection on the X chromosome in great apes, and more.